Japan · Delayed Price · Currency is JPY Astellas Pharma Statistics
Total Valuation
Astellas Pharma has a market cap or net worth of JPY 4.44 trillion. The enterprise value is 4.91 trillion.
| Market Cap | 4.44T |
| Enterprise Value | 4.91T |
Important Dates
The last earnings date was Wednesday, February 4, 2026.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
Astellas Pharma has 1.79 billion shares outstanding. The number of shares has increased by 0.64% in one year.
| Current Share Class | 1.79B |
| Shares Outstanding | 1.79B |
| Shares Change (YoY) | +0.64% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 54.80% |
| Float | 1.79B |
Valuation Ratios
The trailing PE ratio is 13.82 and the forward PE ratio is 16.02. Astellas Pharma's PEG ratio is 0.27.
| PE Ratio | 13.82 |
| Forward PE | 16.02 |
| PS Ratio | 2.15 |
| PB Ratio | 2.51 |
| P/TBV Ratio | 16.13 |
| P/FCF Ratio | 10.90 |
| P/OCF Ratio | 9.69 |
| PEG Ratio | 0.27 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.08, with an EV/FCF ratio of 12.06.
| EV / Earnings | 15.20 |
| EV / Sales | 2.38 |
| EV / EBITDA | 8.08 |
| EV / EBIT | 11.82 |
| EV / FCF | 12.06 |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.41.
| Current Ratio | 1.09 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 1.19 |
| Debt / FCF | 1.78 |
| Interest Coverage | 37.13 |
Financial Efficiency
Return on equity (ROE) is 19.82% and return on invested capital (ROIC) is 16.07%.
| Return on Equity (ROE) | 19.82% |
| Return on Assets (ROA) | 7.38% |
| Return on Invested Capital (ROIC) | 16.07% |
| Return on Capital Employed (ROCE) | 18.28% |
| Weighted Average Cost of Capital (WACC) | 4.05% |
| Revenue Per Employee | 151.04M |
| Profits Per Employee | 23.67M |
| Employee Count | 13,643 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 1.27 |
Taxes
In the past 12 months, Astellas Pharma has paid 66.26 billion in taxes.
| Income Tax | 66.26B |
| Effective Tax Rate | 17.03% |
Stock Price Statistics
The stock price has increased by +69.28% in the last 52 weeks. The beta is 0.05, so Astellas Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.05 |
| 52-Week Price Change | +69.28% |
| 50-Day Moving Average | 2,226.81 |
| 200-Day Moving Average | 1,741.67 |
| Relative Strength Index (RSI) | 61.91 |
| Average Volume (20 Days) | 8,313,305 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Astellas Pharma had revenue of JPY 2.06 trillion and earned 322.91 billion in profits. Earnings per share was 179.17.
| Revenue | 2.06T |
| Gross Profit | 1.67T |
| Operating Income | 416.59B |
| Pretax Income | 389.12B |
| Net Income | 322.91B |
| EBITDA | 608.50B |
| EBIT | 416.59B |
| Earnings Per Share (EPS) | 179.17 |
Balance Sheet
The company has 254.30 billion in cash and 725.28 billion in debt, with a net cash position of -470.98 billion or -262.94 per share.
| Cash & Cash Equivalents | 254.30B |
| Total Debt | 725.28B |
| Net Cash | -470.98B |
| Net Cash Per Share | -262.94 |
| Equity (Book Value) | 1.76T |
| Book Value Per Share | 984.26 |
| Working Capital | 116.68B |
Cash Flow
In the last 12 months, operating cash flow was 457.85 billion and capital expenditures -50.82 billion, giving a free cash flow of 407.03 billion.
| Operating Cash Flow | 457.85B |
| Capital Expenditures | -50.82B |
| Free Cash Flow | 407.03B |
| FCF Per Share | 227.23 |
Margins
Gross margin is 81.00%, with operating and profit margins of 20.22% and 15.67%.
| Gross Margin | 81.00% |
| Operating Margin | 20.22% |
| Pretax Margin | 18.88% |
| Profit Margin | 15.67% |
| EBITDA Margin | 29.53% |
| EBIT Margin | 20.22% |
| FCF Margin | 19.75% |
Dividends & Yields
This stock pays an annual dividend of 78.00, which amounts to a dividend yield of 3.15%.
| Dividend Per Share | 78.00 |
| Dividend Yield | 3.15% |
| Dividend Growth (YoY) | 5.41% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 42.15% |
| Buyback Yield | -0.64% |
| Shareholder Yield | 2.51% |
| Earnings Yield | 7.28% |
| FCF Yield | 9.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 27, 2014. It was a forward split with a ratio of 5.
| Last Split Date | Mar 27, 2014 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Astellas Pharma has an Altman Z-Score of 2.24 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.24 |
| Piotroski F-Score | 7 |